Allogeneic CAR T Company Prepares to Widen Access to Patients

Caribou Biosciences, a company developing donor cell-based CAR T-cell therapy, is preparing to expand patient access through a pivotal Phase III clinical trial. Their allogeneic CAR T-cell therapies have exhibited equal efficacy and duration compared to approved autologous CAR T therapies in treating certain blood cancers. According to Justin Skoble, vice president of technical operations at Caribou Biosciences, utilizing donors under the age of thirty and genome editing strategies have been crucial in optimizing the product.

This approach allows for the development of off-the-shelf products, thereby improving patient access. Currently, 75 to 90% of patients eligible for CAR T therapy do not receive it due to various factors such as disease progression, logistical challenges, socioeconomic barriers, or insurance issues. Caribou Biosciences' allogeneic CAR T-cell therapy eliminates the logistical burden of bespoke manufacturing, as patients can be treated with the product without waiting.

The company's high-fidelity genome-editing technology, chRDNA, minimizes off-target effects and enhances functional persistence. By selecting the best donor match in inventory, Caribou Biosciences ensures low manufacturing costs while maintaining effectiveness. The company hopes their innovative approach will revolutionize the CAR T therapy industry and aims to launch their first product, vispa-cel, as a second-line treatment for large B cell lymphoma in an upcoming randomized-controlled Phase III study.